Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Crenolanib - AROG Pharmaceuticals/Pfizer

Drug Profile

Crenolanib - AROG Pharmaceuticals/Pfizer

Alternative Names: ARO-002; ARO-002-26; CP-868,596; CP-868,596-26; Crenolanib besilate; Crenolanib besylate; IND 112201

Latest Information Update: 27 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer AROG Pharmaceuticals; University of Ulm
  • Class Antineoplastics; Benzimidazoles; Piperidines; Quinolines; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma; Acute myeloid leukaemia; Soft tissue sarcoma; Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia; Gastrointestinal stromal tumours
  • Phase II Glioblastoma; Non-small cell lung cancer
  • Phase I Gastric cancer; Oesophageal cancer
  • Preclinical Systemic mastocytosis
  • Research Soft tissue sarcoma
  • No development reported Glioma

Most Recent Events

  • 28 Feb 2022 AROG Pharmaceuticals terminates phase I clinical trials in Oesophageal cancer and Gastric cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Combination therapy, Inoperable/Unresectable) in USA (PO)
  • 05 Dec 2020 Efficacy and adverse events data from two phase III trials in Acute myeloid leukaemia presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology (ASH-2020)
  • 17 Jul 2020 Arog Pharmaceuticals completes a phase II trial in Glioblastoma (Recurrent, Second-line therapy or greater, Late-stage disease, Monotherapy) in USA (PO) (NCT02626364)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top